Om

ADARx Pharmaceuticals, Inc. is a late-stage biotechnology company focused on developing next-generation siRNA therapeutics. The company works on RNA interference-based medicines designed to silence disease-causing genes and address conditions with significant unmet medical needs. Its current pipeline includes hepatic-targeted programs such as Agazisiran, a complement factor B program, Onvuzosiran for hereditary angioedema attack prevention, and ADX-626, a Factor XI program being studied for thrombotic disease and stroke prevention applications. ADARx Pharmaceuticals operates in the broader genetic medicine and precision therapeutics markets, where it aims to translate advanced oligonucleotide science into targeted treatments across multiple disease areas. Based in San Diego, California, the company is positioned as a clinical biotechnology developer with a focus on translational research and specialty drug development.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I ADARX PHARMACEUTICALS MED ENDAVU: Køb ADARx Pharmaceuticals ($ADRX) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i ADARx Pharmaceuticals, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.